Source:http://linkedlifedata.com/resource/pubmed/id/10552940
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1999-11-30
|
pubmed:abstractText |
Fifty-eight acute promyelocytic leukemia (APL) patients (11 newly diagnosed and 47 relapsed) were studied for arsenic trioxide (As2O3) treatment. Clinical complete remission (CR) was obtained in 8 of 11 (72.7%) newly diagnosed cases. However, As2O3 treatment resulted in hepatic toxicity in 7 cases including 2 deaths, in contrast to the mild liver dysfunction in one third of the relapsed patients. Forty of forty-seven (85.1%) relapsed patients achieved CR. Two of three nonresponders showed clonal evolution at relapse, with disappearance of t(15;17) and PML-RARalpha fusion gene in 1 and shift to a dominant AML-1-ETO population in another, suggesting a correlation between PML-RARalpha expression and therapeutic response. In a follow-up of 33 relapsed cases over 7 to 48 months, the estimated disease-free survival (DFS) rates for 1 and 2 years were 63.6% and 41.6%, respectively, and the actual median DFS was 17 months. Patients with white blood cell (WBC) count below 10 x 10(9)/L at relapse had better survival than those with WBC count over 10 x 10(9)/L (P =.038). The duration of As2O3-induced CR was related to postremission therapy, because there was only 2 of 11 relapses in patients treated with As2O3 combined with chemotherapy, compared with 12 of 18 relapses with As2O3 alone (P =.01). Reverse transcription polymerase chain reaction (RT-PCR) analysis in both newly diagnosed and relapsed groups showed long-term use of As2O3 could lead to a molecular remission in some patients. We thus recommend that ATRA be used as first choice for remission induction in newly diagnosed APL cases, whereas As2O3 can be either used as a rescue for relapsed cases or included into multidrug consolidation/maintenance clinical trials.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:CANAA,
pubmed-author:CaoQQ,
pubmed-author:ChefRR,
pubmed-author:ChenG QGQ,
pubmed-author:ChenS JSJ,
pubmed-author:ChenYY,
pubmed-author:EisEE,
pubmed-author:HuJJ,
pubmed-author:LayJ TJT,
pubmed-author:LiX SXS,
pubmed-author:OKITT,
pubmed-author:RaoM PMP,
pubmed-author:SeuPP,
pubmed-author:ShenZ XZX,
pubmed-author:SuhH JHJ,
pubmed-author:WUA HAH,
pubmed-author:WangZ YZY,
pubmed-author:WaxmanSS,
pubmed-author:WuWW,
pubmed-author:XiongS MSM,
pubmed-author:YangR RRR,
pubmed-author:YapFF,
pubmed-author:YuTT,
pubmed-author:YuanM MMM,
pubmed-author:ZengX YXY,
pubmed-author:ZhangF QFQ,
pubmed-author:ZhangT DTD,
pubmed-author:ZhouLL
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
94
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3315-24
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10552940-Adult,
pubmed-meshheading:10552940-Antineoplastic Agents,
pubmed-meshheading:10552940-Arsenicals,
pubmed-meshheading:10552940-Cell Differentiation,
pubmed-meshheading:10552940-Disease-Free Survival,
pubmed-meshheading:10552940-Drug Monitoring,
pubmed-meshheading:10552940-Female,
pubmed-meshheading:10552940-Follow-Up Studies,
pubmed-meshheading:10552940-Humans,
pubmed-meshheading:10552940-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:10552940-Leukocytosis,
pubmed-meshheading:10552940-Male,
pubmed-meshheading:10552940-Middle Aged,
pubmed-meshheading:10552940-Oxides,
pubmed-meshheading:10552940-Recurrence,
pubmed-meshheading:10552940-Remission Induction,
pubmed-meshheading:10552940-Translocation, Genetic
|
pubmed:year |
1999
|
pubmed:articleTitle |
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
|
pubmed:affiliation |
Shanghai Institute of Hematology, Department of Hematology/Oncology, Rui Jin Hospital/Samuel Waxman Cancer Research Foundation Joint Center for Cancer Differentiation Therapy Sponsored by Reliance Group Holdings Inc, China.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|